TCR-based adoptive therapy employs genetically modified lymphocytes directed against specific tumor markers. T cells (or heterologous T cells), derived from the patient’s peripheral blood, are modified via genetic engineering by adding identified TCR sequences.

These TCR sequences can specifically bind to target antigens. The modified T cells are then transfused back into the patient's body to recognize and kill tumor cells expressing the antigen specificity.​